SZN-8141
Asset
Bifunctional Frizzled 4-mediated Wnt agonist and vascular endothelial growth factor antagonist antibody.
- Stage
- Phase 1
- Modality
- Antibody
- Target
- VEGFA
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Diabetic macular edema
Phase 1, longevity.technology, 5 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors11
Every asset’s record: target, stage, trials and the evidence behind it.